Drug intelligence / Profile preview

[18F]-Compound 9

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Developed by researchers at Tongji Medical College, Huazhong University of Science and Technology, this radiotracer is designed for the non-invasive visualization of total tumor EGFR expression and distribution [EP-0032].

02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
non-small-cell lung cancer (NSCLC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Competitive landscape

Drugs on the same target
328
Drugs in the lead indication
1,797

Lead indication: non-small-cell lung cancer (NSCLC)

Most advanced in the lead indication

  1. erlotinibApproved
  2. ADC 3Approved
  3. albumin (human)Approved
  4. atezolizumabApproved
  5. bevacizumabApproved

Beyond the preview

Go deeper on [18F]-Compound 9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]-Compound 9.

Work on [18F]-Compound 9? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call